Golden Biotechnology Corporation (TPEX: 4132)
Taiwan
· Delayed Price · Currency is TWD 17.35
-0.25 (-1.42%)
Jan 20, 2025, 2:59 PM CST
Golden Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 57.49 | 63.43 | 217.83 | 81.77 | 88.83 | 83.29 | Upgrade
|
| Revenue Growth (YoY) | -69.05% | -70.88% | 166.39% | -7.94% | 6.64% | -8.75% | Upgrade
|
| Cost of Revenue | 55.4 | 47.37 | 66.03 | 69.08 | 64.17 | 38.43 | Upgrade
|
| Gross Profit | 2.1 | 16.06 | 151.79 | 12.69 | 24.66 | 44.87 | Upgrade
|
| Selling, General & Admin | 171.61 | 179.12 | 170.14 | 171.43 | 177.93 | 173.55 | Upgrade
|
| Research & Development | 206.72 | 202.52 | 278.42 | 265.1 | 194.77 | 142.12 | Upgrade
|
| Operating Expenses | 378.32 | 381.64 | 448.56 | 436.53 | 372.59 | 315.33 | Upgrade
|
| Operating Income | -376.23 | -365.58 | -296.77 | -423.85 | -347.94 | -270.46 | Upgrade
|
| Interest Expense | -6.79 | -6.73 | -4.08 | -3.69 | -4.14 | -4.24 | Upgrade
|
| Interest & Investment Income | 5.91 | 8.81 | 4.33 | 0.33 | 0.28 | 0.22 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.05 | 2.52 | 26.56 | -5.82 | -8.13 | -0.67 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.37 | 0.3 | 0.22 | 1.51 | 0.54 | 0.13 | Upgrade
|
| EBT Excluding Unusual Items | -378.43 | -360.68 | -269.74 | -431.52 | -359.4 | -275.03 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.23 | - | -9.26 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.08 | 1.01 | 0.44 | - | -0.48 | - | Upgrade
|
| Asset Writedown | -1.68 | -1.68 | -2.23 | -10.01 | -19.2 | -9.94 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.49 | - | Upgrade
|
| Pretax Income | -379.02 | -361.35 | -271.76 | -441.53 | -388.82 | -284.97 | Upgrade
|
| Income Tax Expense | 0.29 | 0.29 | 0.12 | 2.3 | 2.55 | 0.16 | Upgrade
|
| Net Income | -379.32 | -361.64 | -271.88 | -443.84 | -391.38 | -285.12 | Upgrade
|
| Net Income to Common | -379.32 | -361.64 | -271.88 | -443.84 | -391.38 | -285.12 | Upgrade
|
| Shares Outstanding (Basic) | 142 | 142 | 142 | 132 | 126 | 115 | Upgrade
|
| Shares Outstanding (Diluted) | 142 | 142 | 142 | 132 | 126 | 115 | Upgrade
|
| Shares Change (YoY) | - | - | 7.36% | 5.40% | 9.32% | 2.44% | Upgrade
|
| EPS (Basic) | -2.67 | -2.54 | -1.91 | -3.35 | -3.11 | -2.48 | Upgrade
|
| EPS (Diluted) | -2.67 | -2.54 | -1.91 | -3.35 | -3.11 | -2.48 | Upgrade
|
| Free Cash Flow | -251.92 | -276.2 | -260.3 | -207.31 | -269.02 | -233.88 | Upgrade
|
| Free Cash Flow Per Share | -1.77 | -1.94 | -1.83 | -1.56 | -2.14 | -2.03 | Upgrade
|
| Gross Margin | 3.65% | 25.31% | 69.69% | 15.51% | 27.76% | 53.87% | Upgrade
|
| Operating Margin | -654.40% | -576.36% | -136.24% | -518.35% | -391.71% | -324.71% | Upgrade
|
| Profit Margin | -659.77% | -570.15% | -124.81% | -542.80% | -440.61% | -342.31% | Upgrade
|
| Free Cash Flow Margin | -438.18% | -435.45% | -119.50% | -253.53% | -302.87% | -280.79% | Upgrade
|
| EBITDA | -345.84 | -331.43 | -258.17 | -386.21 | -307.82 | -224.35 | Upgrade
|
| EBITDA Margin | - | - | -118.52% | - | - | -269.34% | Upgrade
|
| D&A For EBITDA | 30.39 | 34.15 | 38.6 | 37.64 | 40.11 | 46.11 | Upgrade
|
| EBIT | -376.23 | -365.58 | -296.77 | -423.85 | -347.94 | -270.46 | Upgrade
|
| EBIT Margin | - | - | -136.24% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.